Health Technology · Pharmaceuticals: Other · NSE: WALPAR · data 2026-10-09

Walpar Nutritions Ltd.

Health check: Weak (0.2/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹26.1

Market cap

—

P/E

—

P/B

—

ROE

—

ROCE

—

Debt / equity

—

Dividend yield

—

1-year return

-36.3%

52-week high

₹50.6

52-week low

₹21.25

Operating margin

—

Growth

Revenue (last 12 months)	—
Net profit (last 12 months)	—
Sales growth, 3 years (yearly)	—
Profit growth, 3 years (yearly)	—

Similar companies

Shri Ahimsa Naturals Limited (SHRIAHIMSA) · Influx Healthtech Limited (INFLUX) · Lyka Labs Limited (LYKALABS) · Sat Kartar Life Limited (SATKARTAR) · Natural Capsules Limited (NATCAPSUQ)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open WALPAR in NSE Scanner →